Orexigen (OREX) Higher Early Following VIVUS (VVUS) Qsymia Approval; Arena (ARNA) Lower
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen (Nasdaq: OREX) is popping higher early Wednesday following late-Tuesday approval of VIVUS (Nasdaq: VVUS) weight-management drug Qsymia.
Shares are up over 6.5 percent while VIVUS recently resumed trading and is indicated higher ahead of the bell.
Arena Pharma (Nasdaq: ARNA), which received FDA approval for its Belviq in June, is also lower ahead of the session.
Shares are up over 6.5 percent while VIVUS recently resumed trading and is indicated higher ahead of the bell.
Arena Pharma (Nasdaq: ARNA), which received FDA approval for its Belviq in June, is also lower ahead of the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Rubio tells allies U.S. shifting focus to Iran sanctions - Axios
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
